亚博网网址B3C新闻专线 B3C新闻专线最新生物科技新闻(短版)亚博网网址//www.whupabstinence.com/ 2020年11月24日星期二11:19:39 +0100 FeedCreator 1.8.3 (obRSS 3.3.10) //www.whupabstinence.com/images/feed-icon-28x28.png 亚博网网址B3C新闻专线 //www.whupabstinence.com/ B3C新闻专线最新生物科技新闻(短版)亚博网网址 en - 野马生物和米纳瑞斯再生医学标志技术转让和GMP制造协议MB-107慢病毒基因治疗x连锁严重联合免疫缺陷 //www.whupabstinence.com/202011232155/mustang-bio-and-minaris-regenerative-medicine-sign-technology-transfer-and-gmp-manufacturing-agreement-for-mb-107-lentiviral-gene-therapy-for-x-linked-severe-combined-immunodeficiency.html > < < tr > < td风格=“宽度:50%;“>,< / td > < td风格=“text-align:没错,”>,< / td > < / tr > < / tbody > < /表> < p > < >强伍斯特的质量。/ B3C newswire / - Mustang Bio, Inc.(“亚博网网址Mustang”)(纳斯达克:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, today announced that they have signed an agreement to enable technology transfer and GMP clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program for the treatment ... 2020年11月23日星期一1400:00 +0100 //www.whupabstinence.com/202011232155/mustang-bio-and-minaris-regenerative-medicine-sign-technology-transfer-and-gmp-manufacturing-agreement-for-mb-107-lentiviral-gene-therapy-for-x-linked-severe-combined-immunodeficiency.html 海洋生物科技公司计划对卡拉胶糖喷鼻剂进行临床试验,以调查一线医护人员COVID-19感染的预防情况 //www.whupabstinence.com/202011202154/marinomed-biotech-plans-clinical-trial-with-carragelose-nasal-spray-to-investigate-prevention-of-covid-19-infection-in-frontline-healthcare-staff.html

First Austrian SARS-CoV-2 prophylactic treatment to be tested in 334 individuals at two clinical sites in Vienna, Austria

VIENNA, Austria, November 20, 2020 / B3C newswire / -- Marinomed Biotech AG (VSE:MARI), a globally operating biopharmaceutical company, announced today plans to initiate a Phase IV clinical trial with Carragelose® (iota-carrageenan). The trial will recruit healthcare professionals, who are managing COVID-19 patients, as study population. The primary objective of the trial is to demonstrate that the prophylactic treatment reduces the symptoms of SARS-CoV-2 and other respiratory viral infections when compared to a placebo-treated control group.

The randomized double blinded trial is expected to ... 2020年11月20日星期五15:05:00 +0100 //www.whupabstinence.com/202011202154/marinomed-biotech-plans-clinical-trial-with-carragelose-nasal-spray-to-investigate-prevention-of-covid-19-infection-in-frontline-healthcare-staff.html COVID-19: FX06在法国开始了对受影响最严重患者的治疗——在命名患者使用中取得了有希望的结果——临床试验 //www.whupabstinence.com/202011192153/covid-19-treatment-for-the-most-severely-affected-patients-after-promising-results-in-named-patient-use-clinical-trial-with-fx06-starts-in-france.html

VIENNA, Austria, November 19, 2020 / B3C newswire / -- F4 Pharma , a clinical-stage biopharmaceutical company developing FX06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, announces today the inclusion of the first patient with severe COVID-19 in a study named “FX-COVID”. The randomized, double-blind, placebo-controlled FX-COVID trial which is conducted by AP-HP  (Assistance Publique –Hopitaux de Paris) in France, is set up to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation. The goal is to show that FX06 infusion - on top of optimal medical treatment - is reducing the extracellular ... 2020年11月19日星期四10:30:00 +0100 //www.whupabstinence.com/202011192153/covid-19-treatment-for-the-most-severely-affected-patients-after-promising-results-in-named-patient-use-clinical-trial-with-fx06-starts-in-france.html 旭日Kasei制药公司将益生菌素用于其生物制品管道的开发 //www.whupabstinence.com/202011182152/asahi-kasei-pharma-contracts-probiogen-for-the-advancement-of-their-biologics-pipeline.html

BERLIN, Germany, November 18, 2020 / B3C newswire / -- ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the CHO.RiGHT® cell line development platform and DirectedLuck™ transposase technology , to enable Asahi Kasei Pharma to advance their biologics pipeline.

“We are enchanted to work with Asahi Kasei Pharma on one of their key projects and are convinced that we can make a difference by applying our inventive technologies”, said Dr. Gabriele Schneider, Chief Business Officer at ... 2020年11月18日星期三1400:00 +0100 //www.whupabstinence.com/202011182152/asahi-kasei-pharma-contracts-probiogen-for-the-advancement-of-their-biologics-pipeline.html BioVersys宣布第一组受试者在BV100一期临床试验中服用的剂量 //www.whupabstinence.com/202011182151/bioversys-announces-first-subjects-dosed-in-phase-1-clinical-trial-of-bv100.html

< p>BV100正在被开发用于治疗由碳青霉烯耐药引起的严重医院感染鲍曼不动杆菌

瑞士巴塞尔,2020年11月18日/ B3C newswire -0  亚博网网址BioVersys has reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, today announced that the first healthy volunteers have received BV100 in a Phase 1 clinical trial designed to evaluate the safety, tolerability, and ... 2020年11月18日星期三000:00 +0100 //www.whupabstinence.com/202011182151/bioversys-announces-first-subjects-dosed-in-phase-1-clinical-trial-of-bv100.html Calypso生物技术宣布成功给1期队列注射抗白介素-15 (IL-15)单克隆抗体CALY-002治疗自身免疫性疾病 //www.whupabstinence.com/202011162150/calypso-biotech-announces-successful-dosing-of-first-phase-1-cohort-with-anti-interleukin-15-il-15-monoclonal-antibody-caly-002-for-the-treatment-of-autoimmune-diseases.html < p > < / p > < p > < >强剂量的研究来评估安全、生物和早期临床效果佳力- 002在健康志愿者和乳糜泻患者和嗜酸性食管炎< /强> < / p > < p > < >强阿姆斯特丹,荷兰,11月16日2020 / B3C新闻专线/ < /强> < a href = " http://www.calypsobiotech.com " target = "平等" rel =“遵循不noopener”>“卡利普索”生物技术< / >,一个公司开发Interleukin-15-targeted生物制剂,亚博网网址今天宣布完成了CALY-002第一阶段临床试验的第一批健康受试者的给药,CALY-002是一种新的人源化单克隆抗体,中和IL-15。CALY-002是我们的il -15靶向生物制品分化流水线的主导项目,我们计划在多种自身免疫性疾病中进行研究。花萼-002有一种独特的作用模式,可以转化为强大的生物… 2020年11月16日,星期一10:00 00 +0100 //www.whupabstinence.com/202011162150/calypso-biotech-announces-successful-dosing-of-first-phase-1-cohort-with-anti-interleukin-15-il-15-monoclonal-antibody-caly-002-for-the-treatment-of-autoimmune-diseases.html 领先制药公司与罗氏公司达成研究合作和许可协议,开发用于免疫介导疾病的口腔小分子 //www.whupabstinence.com/202011162149/lead-pharma-enters-into-a-research-collaboration-and-license-agreement-with-roche-to-develop-oral-small-molecules-for-immune-mediated-diseases.html

  • R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments
  • Lead Pharma may receive payments of up to €260 million plus royalties on sales

OSS, The Netherlands, November 16, 2020 / B3C newswire / -- Lead Pharma , a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated diseases and cancer, today announced that it has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases.

In this single target research collaboration Lead Pharma and Roche ... 2020年11月16日星期一000:00 +0100 //www.whupabstinence.com/202011162149/lead-pharma-enters-into-a-research-collaboration-and-license-agreement-with-roche-to-develop-oral-small-molecules-for-immune-mediated-diseases.html Byondis将出席Jefferies 2020虚拟医疗大会 //www.whupabstinence.com/202011122148/byondis-to-present-at-the-jefferies-2020-virtual-healthcare-conference.html > Byondis今天宣布,其首席执行官Marco Timmers博士将于2020年11月18日星期三(周三)上午09.05 AM 亚博网网址/下午3:05出席Jefferies 2020虚拟医疗大会。The live presentation can be accessed from the Events Calendar on the Byondis website through this link . A replay of the webcast will also be available on the Byondis website following the event.

 

About Byondis (formerly Synthon Biopharmaceuticals)
Driven to improve patients’ lives, Byondis is an independent biopharmaceutical research and development company creating innovative ... 2020年11月12日,星期四000:00 +0100 //www.whupabstinence.com/202011122148/byondis-to-present-at-the-jefferies-2020-virtual-healthcare-conference.html SOTIO介绍了其在SITC 2020年对晚期实体瘤患者进行的SO-C101 1/1b期研究的中期数据 //www.whupabstinence.com/202011112147/sotio-presents-interim-data-from-its-phase-1-1b-study-of-so-c101-in-patients-with-advanced-solid-tumors-at-sitc-2020.html < p > < / p > < ul > <李> <强>末打破海报展示了SO-C101是迄今为止耐受性良好,没有dose-limiting毒性< /强> < /李> <李> <强> C < /强> < >强onfirmed SO-C101单药治疗后局部反应是观察到患者皮肤鳞状细胞癌< /强> < /李> < / ul > < p > < >强布拉格,捷克共和国,11月11日2020 / B3C新闻专线/ < / >强,亚博网网址< a href = " https://www.sotio.com/ " target = "平等rel =“遵循不noopener”> SOTIO < / >,临床阶段immuno-oncology公司Cytune制药,都属于PPF集团今天宣布新的临时数据从其1/1b SO-C101的研究阶段,一个IL-15 superagonist,作为单一疗法,结合pembrolizumab先进/转移性实体瘤患者。这些数据在癌症免疫治疗协会的一份最新发布的海报中被展示出来。 2020年11月11日星期三15:15:00 +0100 //www.whupabstinence.com/202011112147/sotio-presents-interim-data-from-its-phase-1-1b-study-of-so-c101-in-patients-with-advanced-solid-tumors-at-sitc-2020.html 生物医学X研究所宣布扩大他们的战略合作与詹森免疫学研究 //www.whupabstinence.com/202011092146/biomed-x-institute-announces-expansion-of-their-strategic-collaboration-with-janssen-in-immunology-research.html

  • New crowdsourcing project will examine the role of ‘Protective Tissue Factors in Autoimmune Diseases’
  • Call for application for this research program to open now

HEIDELBERG, Germany, November 09, 2020 / B3C newswire / -- German independent research institute BioMed X adds a further research program in the field of immunology to their existing collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson: The new project will focus on the development of novel methodologies to systematically profile and dissect complex tissue microenvironments. The goal is to identify components that induce pro-resolution responses in tissue-resident ... 星期一,2020年11月9日10:00:00 +0100 //www.whupabstinence.com/202011092146/biomed-x-institute-announces-expansion-of-their-strategic-collaboration-with-janssen-in-immunology-research.html ProteoNic宣布将其2G UNic™生物制品生产技术平台授权给吉利德科学公司 //www.whupabstinence.com/202011052145/proteonic-announces-licensing-of-its-2g-unic-technology-platform-for-production-of-biologics-to-gilead-sciences.html

LEIDEN, the Netherlands, November 05, 2020 / B3C newswire / -- ProteoNic , a leading provider of technology and services for efficient production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Gilead Sciences, Inc. (Nasdaq: GILD).  Under the agreement, Gilead gains non-exclusive commercial rights for application of ProteoNic’s technology platform to the development of its proprietary products from mammalian cells. Financial details of the agreement were not disclosed.

ProteoNic’s protein expression technology improves production levels across a range of mammalian host cells and selection systems. It is applicable to all ... 2020年11月5日星期四12:00:00 +0100 //www.whupabstinence.com/202011052145/proteonic-announces-licensing-of-its-2g-unic-technology-platform-for-production-of-biologics-to-gilead-sciences.html 为了在癌症免疫治疗协会(SITC)第35届年会上展示关于IL-15超激动剂SO-C101的新数据 //www.whupabstinence.com/202011042144/sotio-to-present-new-data-on-the-il-15-superagonist-so-c101-at-the-society-for-immunotherapy-of-cancer-sitc-35th-annual-meeting.html

SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors

PRAGUE, Czech Republic, November 04, 2020 / B3C newswire / -- SOTIO , a clinical stage immuno-oncology company, and Cytune Pharma, both owned by PPF Group, today announced that they will present a late breaking poster highlighting new clinical data on SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting to be held virtually November 9-14, 2020. SO-C101 is an IL-15 superagonist currently being investigated in ... 2020年11月04日星期三1500:00 +0100 //www.whupabstinence.com/202011042144/sotio-to-present-new-data-on-the-il-15-superagonist-so-c101-at-the-society-for-immunotherapy-of-cancer-sitc-35th-annual-meeting.html Saillant Therapeutics报告证明其治疗心力衰竭的概念显示功能逆转和心肌再生 //www.whupabstinence.com/202011042143/saillant-therapeutics-reports-proof-of-concept-of-its-treatment-in-heart-failure-showing-functional-reversal-and-myocardial-rejuvenation.html

NIJMEGEN, The Netherlands, November 04, 2020 / B3C newswire / -- Saillant Therapeutics , an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead compound (ST02) indicated for the treatment of heart failure. The compound was tested in a well-established preclinical heart failure model in which it induced a clear reversal to normal of the functional impairments in heart failure, such as Cardiac Output and Ejection Fraction. Moreover, histological reversal demonstrated an unprecedented rejuvenation of myocardial tissue.

These results, with its lead compound, will allow the company to ... 2020年11月04日星期三000:00 +0100 //www.whupabstinence.com/202011042143/saillant-therapeutics-reports-proof-of-concept-of-its-treatment-in-heart-failure-showing-functional-reversal-and-myocardial-rejuvenation.html 听力损失公司Acousia Therapeutics加强研发管理团队 //www.whupabstinence.com/202011022142/hearing-loss-company-acousia-therapeutics-strengthening-its-r-d-management-team.html

TÜBINGEN, Germany, November 02, 2020 / B3C newswire / -- Starting November 1, 2020, Jonas Dyhrfjeld-Johnsen will be joining the Acousia Therapeutics management team in the newly established role of chief development officer. Having worked in various translational R&D positions in the hearing loss and CNS area for more than ten years, Jonas will be further strengthening Acousia`s scientific clout and technical expert network in the field.

„I am extremely pleased to welcome Jonas on board at Acousia Therapeutics“ said CEO Tim Bölke. „Hearing loss is a serious condition of growing epidemic scale and enormous unmet clinical need. Effective drug ... 2020年11月02日星期一09:30:00 +0100 //www.whupabstinence.com/202011022142/hearing-loss-company-acousia-therapeutics-strengthening-its-r-d-management-team.html 米纳里斯再生医学将在德国和日本显著扩大细胞和基因治疗的生产能力 //www.whupabstinence.com/202011022141/minaris-regenerative-medicine-to-significantly-expand-manufacturing-capacity-for-cell-and-gene-therapies-in-germany-and-japan.html

MUNICH, Germany and YOKOHAMA, Japan , November 02, 2020 / B3C newswire / -- Minaris Regenerative Medicine (“Minaris”), a leading global contract development and manufacturing organization for cell and gene therapies, wholly owned by Showa Denko Materials Co., Ltd., announced today a total investment of 64.5 million USD to significantly expand its facilities in Europe and Asia.

European facility expansion:

A new state of the art facility will be built in the proximity of the existing site in Ottobrunn near Munich, Germany with a total investment of 40.7 million USD. The new facility will operate according to GMP standards (FDA and EMA) ... 2020年11月2日星期一08:20:00 +0100 //www.whupabstinence.com/202011022141/minaris-regenerative-medicine-to-significantly-expand-manufacturing-capacity-for-cell-and-gene-therapies-in-germany-and-japan.html